Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Terminated 4Withdrawn 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2Other 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Overweight 1Obesity 1Carcinoma, Signet Ring Cell 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × Biopsy, Needle × Clear all
NCT04291950 2022-12-20

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

University of Arizona

Withdrawn
BreastOther

Breast Neoplasms, Obesity, Overweight, Triple Negative Breast Neoplasms

NCT00903214 2013-04-29

Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Barbara Ann Karmanos Cancer Institute

Phase 1 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡